<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Telomere/Telomerase | BM Sci-Tech Memento</title>
    <link>https://example.com/tag/telomere/telomerase/</link>
      <atom:link href="https://example.com/tag/telomere/telomerase/index.xml" rel="self" type="application/rss+xml" />
    <description>Telomere/Telomerase</description>
    <generator>Wowchemy (https://wowchemy.com)</generator><language>en-us</language>
    <image>
      <url>https://example.com/media/icon_hu1efa9af2edf414d45fb59503b457ea16_13437_512x512_fill_lanczos_center_3.png</url>
      <title>Telomere/Telomerase</title>
      <link>https://example.com/tag/telomere/telomerase/</link>
    </image>
    
    <item>
      <title>Identification of mechanism of cancer-cell-specific reactivation of hTERT offers therapeutic opportunities for blocking telomerase specifically in human colorectal cancer</title>
      <link>https://example.com/article/35697349/</link>
      <pubDate>Wed, 11 Jan 2023 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/35697349/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Transcriptional reactivation of hTERT is the limiting step in tumorigenesis. While mutations in hTERT promoter present in 19% of cancers are recognized as key drivers of hTERT reactivation, mechanisms by which wildtype hTERT (WT-hTERT) promoter is reactivated, in majority of human cancers, remain unknown. Using primary colorectal cancers (CRC) we identified Tert INTeracting region 2 (T-INT2), the critical chromatin region essential for reactivating WT-hTERT promoter in CRCs. Elevated Î²-catenin and JunD level in CRC facilitates chromatin interaction between hTERT promoter and T-INT2 that is necessary to turn on hTERTexpression. Pharmacological screens uncovered salinomycin, which inhibits JunD mediated hTERT-T-INT2 interaction that is required for the formation of a stable transcription complex on the hTERT promoter. Our results showed for the first time how known CRC alterations, such as APC, lead to WT-hTERT promoter reactivation during stepwise-tumorigenesis and provide a new perspective for developing cancer-specific drugs.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
    <item>
      <title>Genome-wide screens identify specific drivers of mutant hTERT promoters</title>
      <link>https://example.com/article/35027447/</link>
      <pubDate>Thu, 13 Jan 2022 00:00:00 +0000</pubDate>
      <guid>https://example.com/article/35027447/</guid>
      <description>&lt;p&gt;&lt;strong&gt;Significance&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Mutations in &lt;em&gt;hTERT&lt;/em&gt; promoter are seen in over 19% of human cancers, irrespective of the cancer type. Understanding the molecular players that regulate Mut-&lt;em&gt;hTERT&lt;/em&gt; promoters may help the design of effective targeting strategies to inhibit telomerase reactivation specifically in cancer cells. Our work uses genome-wide functional screens to identify 30 specific regulators of Mut-&lt;em&gt;hTERT&lt;/em&gt; promoters. These candidates identified from the screening serve as an excellent resource to understand how telomerase is reactivated and as targets for making inhibitors to telomerase, a key driver of cancer.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Abstract&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Cancer-specific &lt;em&gt;hTERT&lt;/em&gt; promoter mutations reported in 19% of cancers result in enhanced telomerase activity. Understanding the distinctions between transcriptional regulation of wild-type (WT) and mutant (Mut) &lt;em&gt;hTERT&lt;/em&gt; promoters may open up avenues for development of inhibitors which specially block &lt;em&gt;hTERT&lt;/em&gt; expression in cancer cells. To comprehensively identify physiological regulators of WT- or Mut-&lt;em&gt;hTERT&lt;/em&gt; promoters, we generated several isogenic reporter cells driven by endogenous &lt;em&gt;hTERT&lt;/em&gt; loci. Genome-wide CRISPR-Cas9 and small interfering RNA screens using these isogenic reporter lines identified specific regulators of Mut-&lt;em&gt;hTERT&lt;/em&gt; promoters. We validate and characterize one of these hits, namely, MED12, a kinase subunit of mediator complex. We demonstrate that MED12 specifically drives expression of &lt;em&gt;hTERT&lt;/em&gt; from the Mut-&lt;em&gt;hTERT&lt;/em&gt; promoter by mediating long-range chromatin interaction between the proximal Mut-&lt;em&gt;hTERT&lt;/em&gt; promoter and &lt;em&gt;T-INT1&lt;/em&gt; distal regulatory region 260 kb upstream. Several hits identified in our screens could serve as potential therapeutic targets, inhibition of which may specifically block Mut-&lt;em&gt;hTERT&lt;/em&gt; promoter driven telomerase reactivation in cancers.&lt;/p&gt;
&lt;ul class=&#34;cta-group&#34;&gt;
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/article/&#34;  class=&#34;btn btn-primary px-3 py-3&#34;&gt;&lt;font color=&#39;white&#39;&gt; &amp;lt; Back to Articles &lt;/font&gt;&lt;/a&gt;
  &lt;/li&gt;
  
  
  &lt;li&gt;
    &lt;a href=&#34;https://example.com/&#34; &gt;
      Alternative to Homepage &lt;i class=&#34;fas fa-angle-right&#34;&gt;&lt;/i&gt;
    &lt;/a&gt;
  &lt;/li&gt;
  
&lt;/ul&gt;

</description>
    </item>
    
  </channel>
</rss>
